GLP-1 RAs, including semaglutide and liraglutide, have shown cardiovascular benefits in patients with type 2 diabetes [34], and emerging evidence suggests tirzepatide—a dual GLP-1/GIP agonist—may offer even greater cardio protection, including among cancer patients [35]. This evidence concerns the gene GCG and type 2 diabetes mellitus.